Fig. 8

MRS5980 reverses cisplatin-induced behavioral deficits. a Male (n = 4/group) and female (n = 4/group) mice were treated with 2 cycles of cisplatin (2.3 mg/kg/day) followed by 24 doses of MRS5980 (0.3 mg/kg/day) starting one day after the last dose of cisplatin. b Mechanical allodynia was measured twice a week using von Frey hairs. Results are expressed as mean ± SEM; Two-way ANOVA (repeated measures) with Tukey's post hoc analysis *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.0)1; ****p ≤ 0.0001. c Effect of MRS5980 on cisplatin-induced spontaneous pain as measured in CPP test after 4 weeks after the last dose of MRS5980. Y-axis indicates the change in time spent in the bright (analgesic-paired chamber) between baseline and test. d Effect of MRS5980 after completion of cisplatin treatment on executive functioning measured using the PBT as assessed one week after the last dose of MRS5980. Mean of the time in seconds it takes to enter the dark compartment in the hard trial of the PBT. e Effect of MRS5980 after completion of cisplatin treatment on spatial and working memory. Preference for the novel object in the NOPRT is presented as discrimination index (DI) as in Fig. 1C. f Influence of MRS5980 on cisplatin-induced sensorimotor deficits. Mice were tested on three different beams of increasing difficulty and the time to cross the round beam is depicted. Results are expressed as mean ± SEM; Two-way ANOVA with Tukey's post hoc analysis *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001. Black circles (male mice) and grey circles (female mice)